DEXA Bone Density: What 'Normal' Actually Means vs. What's Optimal for Your Bones

What a DEXA Scan Actually Measures

A DEXA (dual-energy X-ray absorptiometry) scan measures bone mineral density (BMD) at specific sites, most commonly the lumbar spine (L1-L4) and the femoral neck or total hip. The machine sends two low-dose X-ray beams through the bone and calculates how much mineral, primarily calcium hydroxyapatite, is present per square centimeter. That number is then compared to two reference groups to produce two separate scores.

The scan takes roughly 10-30 minutes, delivers an effective radiation dose of about 1-10 microsieverts, which is less than a single day of background radiation, and requires no contrast or injections.

T-Score: The "Normal vs. Abnormal" Number

Your T-score compares your BMD to the average peak BMD of a healthy young adult woman (age 20-29, female reference database). The World Health Organization's 1994 diagnostic criteria, still in use today, defined the three categories this way:

| T-score | WHO Category | |---|---| | -1.0 and above | Normal | | -1.0 to -2.5 | Osteopenia (low bone mass) | | -2.5 and below | Osteoporosis | | -2.5 and below + fragility fracture | Severe osteoporosis |

Z-Score: The Score That Matters More If You Are Younger

Your Z-score compares your BMD to women of your own age and ethnicity. ISCD (International Society for Clinical Densitometry) guidelines recommend using Z-scores rather than T-scores to interpret DEXA results in premenopausal women, children, and men under 50. A Z-score below -2.0 in a premenopausal woman flags BMD that is "below the expected range for age" and warrants a secondary-cause workup, not an automatic osteoporosis diagnosis based on the T-score alone.

This distinction matters. A 35-year-old woman with a T-score of -2.2 may have a Z-score of -0.5, meaning her bone density is actually typical for her age group. Treating that T-score as a fracture-risk emergency without checking the Z-score is a clinical error worth catching.

The Gap Between "Normal" and Optimal

The WHO cutoffs were designed to classify populations for epidemiological research, not to tell any individual woman the safest place to be. The T-score scale was anchored to a white, postmenopausal female population in the original WHO study. That history matters for two reasons.

First, a T-score of -0.9 is "normal" by definition, but it represents bone density meaningfully lower than your personal peak. Second, fracture risk rises continuously along the BMD curve, not in a sharp step at -2.5. A woman with a T-score of -1.8 carries substantially more fracture risk than one at -0.5, even though both are categorized as osteopenia.

A more useful way to think about your score is a three-zone framework:

Zone 1 (T-score 0 to +1.0): Structural reserve. You have bone density above average for a young adult. Your fracture risk is low, and the clinical goal is preservation through diet, exercise, and lifestyle.

Zone 2 (T-score -1.0 to -1.5): Watch closely. This is the zone where most perimenopausal women quietly drift without knowing it. No medication is typically indicated here, but annual monitoring, protein intake targets, resistance training, and vitamin D optimization become high-priority actions rather than optional suggestions.

Zone 3 (T-score -1.5 to -2.5): Act now, medication likely ahead. The FRAX fracture-risk calculator integrates T-score with clinical risk factors (prior fracture, parental hip fracture, smoking, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis, and alcohol). At a 10-year major osteoporotic fracture probability above 20%, or hip fracture probability above 3%, the National Osteoporosis Foundation and American College of Rheumatology recommend initiating pharmacotherapy even without a T-score of -2.5.

How Bone Density Changes Across Your Life Stages

Reproductive Years (Ages 20-40)

Peak bone mass is reached, on average, by the late 20s to early 30s. Approximately 90% of peak bone mass is accrued by age 18 in girls, with the final consolidation happening in the third decade. The decisions that matter most for peak bone mass are happening during adolescence and early adulthood, including calcium and vitamin D intake, physical activity, and avoiding low energy availability.

Female athletes and women with a history of hypothalamic amenorrhea, eating disorders, or chronic low caloric intake may reach their 30s with a Z-score already below -1.0. The Female Athlete Triad, now updated to the Relative Energy Deficiency in Sport (RED-S) model, documents this clearly: energy deficiency suppresses estrogen, estrogen suppression accelerates bone resorption, and the deficit is only partially reversible.

Trying to Conceive and Pregnancy

DEXA is not routinely ordered during pregnancy. Bone metabolism shifts considerably in pregnancy: maternal bone may contribute calcium to the fetus, but most studies show BMD returns to pre-pregnancy levels by 12-18 months postpartum. Transient bone loss during pregnancy and lactation is largely physiologic.

Pregnancy-associated osteoporosis (PAO) is rare, estimated at 0.4 per 100,000 deliveries, but it does occur, typically presenting as vertebral compression fractures in the third trimester or early postpartum period. Women with a personal or family history of early fracture, prolonged heparin use, or low Z-scores pre-pregnancy warrant closer monitoring.

Postpartum and Lactation

Lactation drives the most significant short-term bone loss outside of menopause. Exclusively breastfeeding women lose 3-9% of spine BMD over 3-6 months of full lactation, driven by elevated parathyroid hormone-related protein (PTHrP) and suppressed estrogen. The good news: BMD typically recovers fully within 6-12 months after weaning, provided nutritional status is adequate.

Supplemental calcium (1,000-1,200 mg/day total from all sources) and vitamin D (600-2,000 IU/day depending on serum 25-OH vitamin D status) during lactation support both bone recovery and milk mineral content. DEXA screening is not recommended during lactation for average-risk women unless clinical suspicion of PAO exists.

Perimenopause (Ages 40-52 approximately)

This is the life stage where DEXA results most often surprise women. The perimenopausal transition brings erratic, then falling, estrogen levels, and estrogen is the primary brake on osteoclast (bone-resorbing cell) activity. Bone loss accelerates to 1-3% per year during the perimenopausal transition, compared to 0.5-1% per year in the stable premenopausal state.

The first 5 years after the final menstrual period carry the steepest decline. Trabecular bone (the spongy inner structure of vertebrae and femoral neck) is more estrogen-sensitive than cortical bone and loses density faster. This is why spine T-scores often fall faster than hip T-scores in early menopause.

A perimenopausal woman who gets her first DEXA at 48 and sees a T-score of -1.6 may not realize she started that decade at -0.8. The trend matters as much as the number.

Postmenopause

USPSTF recommends universal DEXA screening beginning at age 65 for women with no prior fracture and no known osteoporosis. Screening before 65 is recommended for postmenopausal women under 65 whose 10-year fracture risk, calculated with FRAX, equals or exceeds that of a 65-year-old white woman with no additional risk factors (approximately 9.3%).

Roughly 1 in 2 women over 50 will experience an osteoporotic fracture in her lifetime. Hip fracture carries a 20-30% one-year mortality rate in older women, a fact that puts the clinical stakes into perspective.

What a "High" DEXA Result Means

A positive T-score (above 0) means your bone density is above the young-adult female average. There is no clinical upper threshold of concern for bone density in the context of a standard DEXA scan. High bone density is generally a favorable finding.

One caveat worth noting: very high BMD at the spine in isolation may occasionally reflect osteophytes (degenerative bone spurs from arthritis) or aortic calcification artifact inflating the L-spine number. If your spine T-score is substantially higher than your hip T-score and you have known degenerative disc disease, ask your provider whether the spine reading is interpretable or whether the hip score should guide clinical decisions.

What a "Low" DEXA Result Means (and What to Do About It)

Low bone density on DEXA, whether osteopenia or osteoporosis, is not a single diagnosis requiring a single treatment. The appropriate response depends on your T-score, your Z-score, your age and hormonal status, your FRAX score, and your secondary-cause evaluation.

Secondary Causes to Rule Out First

Before accepting "idiopathic osteoporosis" or simply prescribing a bisphosphonate, a thorough clinician will check for secondary causes. In women, the most common are:

• Estrogen deficiency (surgical or natural menopause, hypothalamic amenorrhea, premature ovarian insufficiency)
• Vitamin D deficiency (25-OH vitamin D below 30 ng/mL affects calcium absorption; below 20 ng/mL is overt deficiency)
• Celiac disease (impairs calcium and vitamin D absorption; prevalence in osteoporotic women may be 3-4x general population)
• Hyperthyroidism and overtreatment with levothyroxine (excess thyroid hormone directly stimulates osteoclasts)
• Primary hyperparathyroidism (elevated PTH drives bone resorption)
• Glucocorticoid use (even inhaled steroids at high doses over years)
• PCOS with low estrogen states (though many women with PCOS have normal or above-average BMD due to higher androgen levels)

A basic secondary-cause lab panel includes: serum calcium, phosphorus, albumin, creatinine, 25-OH vitamin D, PTH, TSH, CBC, and in premenopausal women with irregular cycles, FSH and estradiol.

When Medication Is Indicated

AACE/ACE guidelines indicate pharmacotherapy for postmenopausal women with:

• T-score at or below -2.5 at the spine, femoral neck, or total hip
• T-score between -1.0 and -2.5 with a 10-year FRAX major fracture probability at or above 20%, or hip fracture probability at or above 3%
• A prior fragility fracture (hip or vertebral fracture qualifies regardless of T-score)

Alendronate (70 mg once weekly orally) is the most commonly prescribed first-line bisphosphonate for postmenopausal osteoporosis. A 2022 Cochrane review confirmed alendronate reduces vertebral fracture risk by approximately 45% and hip fracture risk by approximately 40% relative to placebo in women with osteoporosis. The number needed to treat to prevent one vertebral fracture over 3 years is approximately 20.

Alternatives include risedronate, zoledronic acid (IV, once yearly), denosumab (injection every 6 months), and for women with postmenopausal osteoporosis at high fracture risk, anabolic agents like teriparatide or romosozumab. Menopausal hormone therapy (MHT) preserves bone density and reduces fracture risk, and may be particularly appropriate for younger postmenopausal women who also have vasomotor symptoms. The Menopause Society (formerly NAMS) position statement notes that MHT is an acceptable option for fracture prevention in women under 60 or within 10 years of menopause onset.

Non-Pharmacological Strategies to Raise Bone Density

Lifestyle measures are not placebo. They are the foundation of bone health at every life stage and may be sufficient to stabilize or modestly improve bone density in Zone 2.

Resistance training and impact exercise. Bone responds to mechanical load. A meta-analysis of 18 randomized controlled trials found that resistance training improved lumbar spine BMD by approximately 1-2% over 6-12 months in postmenopausal women. Weight-bearing aerobic exercise (walking, jogging, dancing) adds additional benefit.

Calcium intake. Total dietary plus supplemental calcium of 1,000 mg/day for women under 50, and 1,200 mg/day for women 50 and older, is the NIH Office of Dietary Supplements recommendation. Calcium from food sources (dairy, fortified plant milks, leafy greens, canned fish with bones) is absorbed more efficiently than supplement-only approaches.

Vitamin D. Endocrine Society guidelines recommend maintaining serum 25-OH vitamin D above 30 ng/mL; doses of 1,500-2,000 IU/day are often needed to reach that target in women with baseline deficiency.

Protein intake. Adequate protein (1.2-1.6 g/kg/day) supports the collagen matrix of bone, not just muscle mass. Low protein intake amplifies the negative effect of low estrogen on bone.

Smoking cessation and alcohol moderation. Smoking directly impairs osteoblast function. Heavy alcohol use (more than 2 drinks/day regularly) suppresses bone formation and increases fall risk.

How Often Should You Repeat Your DEXA?

Repeat interval depends on your baseline T-score and clinical context. The Endocrine Society suggests:

| Baseline T-score | Suggested Repeat Interval | |---|---| | Normal (-1.0 to 0) | 10-15 years | | Mild osteopenia (-1.0 to -1.5) | 5 years | | Moderate osteopenia (-1.5 to -2.0) | 2-3 years | | Advanced osteopenia (-2.0 to -2.5) | 1-2 years | | On pharmacotherapy | 1-2 years to assess treatment response |

Women entering perimenopause with a baseline scan in the osteopenia range benefit from a repeat at 2 years rather than waiting the "standard" 5-year interval, because the rate of perimenopausal bone loss can be fast enough that a treatment threshold is crossed between scans.

DEXA and PCOS: A Nuanced Picture

Women with PCOS present an interesting bone-health paradox. Higher androgen levels (testosterone, DHEA-S) and higher body weight, both common in PCOS, are independently associated with higher BMD. A 2020 meta-analysis in JCEM found women with PCOS had slightly higher spine and hip BMD than age-matched controls in most studies.

But this is not universal protection. Women with PCOS who have prolonged amenorrhea or oligomenorrhea due to hypothalamic suppression (common in lean PCOS or after aggressive caloric restriction) may have estrogen levels low enough to impair bone accrual, particularly in the spine. The protection offered by androgens and body weight does not fully compensate for estrogen deficiency when estrogen is truly low.

Racial and Ethnic Differences in BMD Reference Ranges

The original WHO criteria were built on white European female data. Black American women have higher BMD on average than white women at equivalent ages, yet experience similar absolute fracture rates at comparable T-scores. Asian American women generally have lower raw BMD measurements but similar fracture incidence compared to white women at the same T-score. Hispanic women fall between.

This means the T-score thresholds for pharmacotherapy, derived from white reference populations, may systematically over-diagnose osteoporosis in Black women and under-diagnose fracture risk in Asian women. FRAX incorporates race/ethnicity in its algorithm, which is one reason FRAX is preferred over T-score alone for treatment decisions in ethnically diverse populations.

The Evidence Gap: Where Women-Specific Data Are Thin

Women have been central to most osteoporosis research, which is one of the few areas where female physiology has received adequate study. The primary evidence gap is in younger premenopausal women with low bone density: most fracture-prevention trials enrolled women over 55, so treatment recommendations for a 38-year-old with a Z-score of -2.5 rest on physiologic reasoning and case series rather than large RCT data. Treatment in premenopausal women should be managed by a specialist in metabolic bone disease or endocrinology.

A second gap: most DEXA reference databases used by manufacturers were built on non-Hispanic white women. The clinical impact of applying those norms to other populations is recognized but not fully resolved.

As WomanRx medical reviewer Rachel Goldberg, MD, puts it: "The T-score is a starting point, not a sentence. I want to know where a woman is trending, what her estrogen status is, what she's eating, and whether she's lifting weights, before I decide if a medication conversation is premature or overdue."